Febuxostat - Teijin Pharma

Drug Profile

Febuxostat - Teijin Pharma

Alternative Names: Adenuric; Feburic; Febuxostat XR; TEI-6720; TMX 67XR; TMX-67; Uloric

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Teijin Pharma
  • Developer Astellas Pharma; Ipsen; Menarini; SK Chemicals; Takeda Pharmaceuticals USA; Teijin Pharma
  • Class Antigouts; Carboxylic acids; Nitriles; Phenyl ethers; Small molecules; Thiazoles
  • Mechanism of Action Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperuricaemia
  • Registered Tumour lysis syndrome
  • Phase II Hypertension
  • Suspended Angina pectoris

Most Recent Events

  • 12 Mar 2018 Safety data from the phase IIIb CARES trial for Hyperuricaemia (in patients with gout and cardiovascular co-morbidities) released by Takeda Pharmaceuticals
  • 15 May 2017 Takeda completes the phase IIIb CARES trial for Hyperuricaemia (in patients with gout and cardiovascular co-morbidities) in USA and Mexico (PO, Capsule) (NCT01101035)
  • 10 May 2017 Discontinued - Phase-III for Hyperuricaemia (in patients with gout) in USA (PO,Controlled-release) before May 2017 (Takeda FY2016 results, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top